BLA 125390 · Chiesi Farmaceutici Spa
Myalept
Metreleptin · Injection · Leptin Analog
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Feb 24, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
35
6 Phase 3, 4 recruiting
FAERS reports
1,263
654 serious, 71 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF LYMPHOMA Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with MYALEPT. The consequences of these neutralizing antibodies are not well characterized but could include inhibition of endogenous leptin action and/or loss of MYALEPT efficacy. Severe infection and/or worsening metabolic control have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs suspicious for loss of MYALEPT efficacy during treatment. Contact Chiesi Farmaceutici S.p.A. at 1-866-216-1526 for neutralizing antibody testing of clinical samples [see Contraindications (4.1) and Warnings and Precautions (5.1) ]. T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and...
What it is approved for
From the label in effect Mar 25, 2024.
MYALEPT is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. ( 1 ) Limitations of Use The safety and effectiveness of MYALEPT for the treatment of complications of partial lipodystrophy have not been established. ( 1 ) The safety and effectiveness of MYALEPT for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established. ( 1 ) MYALEPT is not indicated for use in patients with HIV-related lipodystrophy. ( 1 ) MYALEPT is not indicated for use in patients with metabolic disease, without concurrent evidence of generalized lipodystrophy. ( 1 ) 1.1 Patients with Generalized Lipodystrophy MYALEPT (metreleptin) for injection is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Limitations of Use The safety and effectiveness of MYALEPT for the treatment of complications of partial lipodystrophy have not been established. The safety and effectiveness of MYALEPT for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established. MYALEPT is not indicated for use in patients with HIV-related lipodystrophy. MYALEPT is not indicated for use in patients with metabolic disease, including diabetes mellitus and hypertriglyceridemia, without concurrent evidence of congenital or acquired generalized lipodystrophy.
Mechanism: Adipocytes store lipids to meet the fuel requirements of non-adipose tissues during fasting. In patients with generalized lipodystrophy, the deficiency of adipose tissue leads to hypertriglyceridemia and ectopic deposition of fat in non-adipose tissues such as liver and muscle, contributing to metabolic abnormalities including insulin resistance. Native leptin is a hormone predominantly secreted by adipose tissue that informs the central nervous system of the status of energy stores in the body. In patients with generalized lipodystrophy, leptin deficiency, resulting from the loss of adipose...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 24, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewOther
1 products under this application
- MYALEPT · METRELEPTIN 11.3MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Metreleptin" as an intervention, any sponsor and status, largest first.
- Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00673387 · 636 participants · Start Apr 2008 · Primary completion Apr 2009
Drug: pramlintide acetate; metreleptin and 2 more · For: Overweight; Obesity
Sites: Birmingham, Alabama; Chandler, Arizona; Santa Rosa, California · 36 sites in all
- Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00819234 · 274 participants · Start Nov 2008 · Primary completion Oct 2009
Drug: Placebo; Pramlintide and Metreleptin · For: Obesity
Sites: Birmingham, Alabama; Phoenix, Arkansas; Santa Rosa, California · 33 sites in all
- A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsPivotal-lookingTerminated
AstraZenecaAstraZeneca (AZN)
NCT01235741 · 213 participants · Start Jan 2011 · Primary completion Sep 2011
Drug: Pramlintide+Metreleptin; Placebo · For: Obesity
Sites: Greenbrae, California; La Jolla, California; Denver, Colorado · 18 sites in all
- A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese SubjectsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00392925 · 177 participants · Start Oct 2006 · Primary completion Sep 2007
Drug: pramlintide acetate 360 mcg; metreleptin and 3 more · For: Overweight; Obesity
Sites: DeLand, Florida; Chicago, Illinois; Indianapolis, Indiana · 12 sites in all
- Leptin to Treat LipodystrophyCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00025883 · 103 participants · Start Oct 2001 · Primary completion Feb 2015
Drug: Metreleptin · For: Lipodystrophy
Sites: Bethesda, Maryland
- Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT05164341 · 69 participants · Start Dec 17, 2021 · Primary completion Jul 14, 2026
Drug: metreleptin; Placebo · For: Partial Lipodystrophy
Sites: Birmingham, Alabama; Sacramento, California; Boca Raton, Florida · 31 sites in all
- Metreleptin in Anorexia NervosaRecruiting
Gabriella MilosAcademic, hospital or other
NCT06305182 · 50 participants (planned) · Start May 31, 2024 · Primary completion Dec 31, 2026
Drug: Metreleptin; Sodium chloride · For: Anorexia Nervosa
Sites: Zurich, Switzerland
Rockefeller UniversityAcademic, hospital or other
NCT00050791 · 40 participants (planned) · Start Mar 2001 · Primary completion Nov 2006
Drug: Leptin · For: Obesity
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue102
- weight decreased93
- therapy cessation92
- blood glucose increased84
- drug ineffective77
- off label use68
- therapy interrupted66
- nausea61
- blood triglycerides increased54
- treatment noncompliance53
- weight increased52
- injection site pain48
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 15 |
| 2015 | 51 |
| 2016 | 95 |
| 2017 | 87 |
| 2018 | 89 |
| 2019 | 140 |
| 2020 | 203 |
| 2021 | 74 |
| 2022 | 93 |
| 2023 | 111 |
| 2024 | 134 |
| 2025 | 70 |
| 2026 | 101 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Myalept (Metreleptin)
2024 spending
$15.3M
Beneficiaries
12
102 claims
Per beneficiary
$1,278,883
$6,572.42 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,396,955 |
| 2021 | $17,962,350 |
| 2022 | $17,141,562 |
| 2023 | $17,122,465 |
| 2024 | $15,346,595 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Classification of Congenital Leptin Deficiency.
von Schnurbein J, Zorn S, Nunziata A, et al. · J Clin Endocrinol Metab 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Leptin increases hepatic triglyceride export via a vagal mechanism in humans.
Metz M, Beghini M, Wolf P, et al. · Cell Metab 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Leptin acutely increases hepatic triglyceride secretion in patients with lipodystrophy.
Beghini M, Metz M, Baumgartner C, et al. · Metabolism 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown RJ, Valencia A, Startzell M, et al. · J Clin Invest 2018 · Clinical Trial, Research Support, N.I.H., Intramural
- Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
Grover A, Quaye E, Brychta RJ, et al. · J Clin Endocrinol Metab 2021 · Clinical Trial, Research Support, N.I.H., Extramural
- Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan JL, Koda J, Heilig JS, et al. · Clin Endocrinol (Oxf) 2016 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Chiesi Farmaceutici Spa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.